Search

Febbo, P. G., M. Lowenberg, A. R. Thorner, M. Brown, M. Loda, and T. R. Golub. 2005. “Androgen Mediated Regulation and Functional Implications of Fkbp51 Expression in Prostate Cancer”. J Urol 173: 1772-7.

Frohling, S., C. Scholl, R. L. Levine, M. Loriaux, T. J. Boggon, O. A. Bernard, R. Berger, et al. 2007. “Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles”. Cancer Cell 12: 501-13.

Garraway, L. A., H. R. Widlund, M. A. Rubin, G. Getz, A. J. Berger, S. Ramaswamy, R. Beroukhim, et al. 2005. “Integrative Genomic Analyses Identify MITF As a Lineage Survival Oncogene Amplified in Malignant Melanoma”. Nature 436: 117-22.

Golub, T. R. 2001. “Genome-Wide Views of Cancer”. N Engl J Med 344: 601-2.

Golub, T. R. 2003. “Mining the Genome for Combination Therapies”. Nat Med 9: 510-1.

Golub, T. R. 2007. “Genomics: Global Views of Leukaemia”. Nature 446: 739-40.

Golub, T. R., G. F. Barker, K. Stegmaier, and D. G. Gilliland. 1996. “Involvement of the TEL Gene in Hematologic Malignancy by Diverse Molecular Genetic Mechanisms”. Curr Top Microbiol Immunol 211: 279-88.

Halmos, B., D. S. Basseres, S. Monti, F. D’Alo, T. Dayaram, K. Ferenczi, B. J. Wouters, C. S. Huettner, T. R. Golub, and D. G. Tenen. 2004. “A Transcriptional Profiling Study of CCAAT/Enhancer Binding Protein Targets Identifies Hepatocyte Nuclear Factor 3 Beta As a Novel Tumor Suppressor in Lung Cancer”. Cancer Res 64: 4137-47.

Hoshida, Y., and T. R. Golub. 2009. “Prolonged Therapy for Hepatitis C With Low-Dose Peginterferon”. N Engl J Med 360: 1152; author reply 1152-3.

Stathias, V., A. M. Jermakowicz, M. E. Maloof, M. Forlin, W. Walters, R. K. Suter, M. A. Durante, et al. 2018. “Drug and Disease Signature Integration Identifies Synergistic Combinations in Glioblastoma”. Nat Commun 9: 5315.